Checkpoint Therapeutics, Inc. Quarterly report pursuant to Section 13 or 15(d)

Accounts Payable and Accrued Expenses

9 Months Ended

Sep. 30, 2019

Note 7 - Accounts Payable and Accrued Expenses

At September 30, 2019 and December 31, 2018, accounts payable and accrued expenses consisted of the following ($ in thousands):


	September 30,		December 31,
	2019		2018
Accounts payable	$	3,728	$	9,750
Accrued compensation		293		439
Research and development		2,601		1,751
Other		285		377
Accounts payable and accrued expenses - related party		904		776
Total accounts payable and accrued expenses	$	7,811	$	13,093